Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis → The Presidential candidate you should REALLY be worried about (From Stansberry Research) (Ad) Free AXSM Stock Alerts $75.19 +1.01 (+1.36%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$74.19▼$75.4150-Day Range$65.72▼$80.8652-Week Range$55.02▼$98.40Volume377,246 shsAverage Volume555,591 shsMarket Capitalization$3.57 billionP/E RatioN/ADividend YieldN/APrice Target$121.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside62.1% Upside$121.92 Price TargetShort InterestBearish16.23% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment1.03Based on 7 Articles This WeekInsider TradingSelling Shares$3.99 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.70) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.73 out of 5 starsMedical Sector57th out of 923 stocksPharmaceutical Preparations Industry21st out of 429 stocks 4.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.23% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 0.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 3.4 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search Interest16 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,994,220.00 in company stock.Percentage Held by Insiders22.40% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.70) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 24.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWARNING about the death of the U.S. dollar…Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide. About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesMay 23 at 1:16 AM | americanbankingnews.comInvestors Buy Large Volume of Call Options on Axsome Therapeutics (NASDAQ:AXSM)May 20, 2024 | markets.businessinsider.comHold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization ProspectsMay 18, 2024 | fool.com3 Monster Stocks in the Making You Can Buy Right NowMay 17, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (AXSM)May 13, 2024 | finance.yahoo.com15 Most Depressed States in the USMay 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11, 2024 | fool.comPrediction: These 2 Growth Stocks Could Triple By 2030May 10, 2024 | seekingalpha.comWhy Axsome Therapeutics Is A Promising Stock Pick In CNS TreatmentsMay 9, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 8, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical TrialsMay 8, 2024 | globenewswire.comAxsome Therapeutics to Present at Upcoming Investor ConferencesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic PositioningMay 7, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion PotentialMay 7, 2024 | finance.yahoo.comAxsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...May 7, 2024 | finance.yahoo.comQ1 2024 Axsome Therapeutics Inc Earnings CallMay 6, 2024 | fool.comAxsome Therapeutics (AXSM) Q1 2024 Earnings Call TranscriptMay 6, 2024 | investorplace.comAXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | washingtonpost.comAxsome: Q1 Earnings SnapshotMay 6, 2024 | msn.comAxsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15MMay 6, 2024 | globenewswire.comAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | stocknews.comInvestors Beware of These 3 Pharma StocksMay 1, 2024 | globenewswire.comAxsome Therapeutics Recognizes May as Mental Health Awareness MonthApril 30, 2024 | investorplace.com3 Biotech Stocks with Blockbuster Drug Pipelines: April EditionApril 29, 2024 | finance.yahoo.comGinkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of DirectorsSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today5/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$121.92 High Stock Price Target$190.00 Low Stock Price Target$81.00 Potential Upside/Downside+62.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($6.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-118.07% Pretax Margin-118.71% Return on Equity-87.17% Return on Assets-32.81% Debt Debt-to-Equity Ratio1.25 Current Ratio3.20 Quick Ratio3.09 Sales & Book Value Annual Sales$270.60 million Price / Sales13.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.03 per share Price / Book24.82Miscellaneous Outstanding Shares47,500,000Free Float36,857,000Market Cap$3.57 billion OptionableOptionable Beta1.13 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kKey CompetitorsInsmedNASDAQ:INSMHUTCHMEDNASDAQ:HCMBiohavenNYSE:BHVNUltragenyx PharmaceuticalNASDAQ:RAREPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsAlethea Capital Management LLCSold 11,253 shares on 5/17/2024Ownership: 1.560%Artal Group S.A.Bought 76,837 shares on 5/17/2024Ownership: 0.162%Castleark Management LLCBought 32,200 shares on 5/17/2024Ownership: 0.068%Comerica BankBought 8,951 shares on 5/17/2024Ownership: 0.019%Walleye Trading LLCSold 1,200 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price target for 2024? 13 analysts have issued 1-year target prices for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $190.00. On average, they predict the company's share price to reach $121.92 in the next twelve months. This suggests a possible upside of 62.1% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2024? Axsome Therapeutics' stock was trading at $79.59 at the beginning of 2024. Since then, AXSM shares have decreased by 5.5% and is now trading at $75.19. View the best growth stocks for 2024 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Monday, November, 6th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.24) by $0.08. The company had revenue of $57.79 million for the quarter, compared to analysts' expectations of $54.88 million. Axsome Therapeutics had a negative net margin of 118.07% and a negative trailing twelve-month return on equity of 87.17%. During the same quarter in the previous year, the firm posted ($1.03) earnings per share. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.87%), Alethea Capital Management LLC (1.56%), Bellevue Group AG (1.44%), Hood River Capital Management LLC (1.10%), Affinity Asset Advisors LLC (0.29%) and Healthcare of Ontario Pension Plan Trust Fund (0.29%). Insiders that own company stock include Mark Coleman, Mark E Saad, Mark L Jacobson, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXSM) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe Presidential candidate you should REALLY be worried aboutStansberry ResearchThis could mean the end of the U.S dollar…Colonial MetalsJust $9 for a Year of Winning Market InsightsBehind the MarketsI’m afraid WWIII is a very real possibility Porter & CompanyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeBitcoin’s Biggest Year YetParadigm PressNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.